Citation Tools

PDF

OP0313 COST-EFFECTIVENESS OF A JAK1/JAK2-INHIBITOR VS. A BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG IN A TREAT-TO-TARGET STRATEGY FOR RHEUMATOID ARTHRITIS

Download to a citation manager

Cite this article as:
Laar CVD, Voshaar MO, Fakhouri W, et al
OP0313 COST-EFFECTIVENESS OF A JAK1/JAK2-INHIBITOR VS. A BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG IN A TREAT-TO-TARGET STRATEGY FOR RHEUMATOID ARTHRITIS